

Novavax, Inc. Securities Settlement
c/o Strategic Claims Services, Inc.
600 N. Jackson St., Suite 205
Media, PA 19063

COURT-ORDERED LEGAL NOTICE

Sinnathurai v. Novavax, Inc., et al.,
No. 8:21-cv-02910-TDC (D. Md.)

**Your legal rights may be affected by
this securities class action settlement.
You may be eligible for a cash payment.
Please read this postcard carefully.**

**For more information, please visit
www.strategicclaims.net/novavax/
or call (866) 274-4004**



THIS POSTCARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.
PLEASE VISIT WWW.STRATEGICCLAIMS.NET/NOVAVAX/ FOR MORE INFORMATION.

The Parties in the class action *Sinnathurai v. Novavax, Inc., et al.*, 8:21-cv-02910-TDC (D. Md.) have reached a proposed settlement of the claims against Defendants. If approved, the Settlement will resolve a lawsuit in which Plaintiffs alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Defendants deny any liability or wrongdoing. You received this postcard because you, or an investment account for which you serve as a custodian, may be a member of the Settlement Class: **all persons or entities who or which, during the period from May 11, 2021 through October 19, 2021, inclusive (“Class Period”), purchased or otherwise acquired the publicly traded common stock of Novavax, Inc. and were damaged thereby.**

Pursuant to the Settlement, Defendants have agreed to pay \$47,000,000. This amount, plus accrued interest, after deduction of Court-awarded attorneys’ fees and expenses, Notice and Administration Expenses, and Taxes, will be allocated among Settlement Class Members who submit valid claims, in exchange for the settlement of the Action and the release of all claims asserted in the Action and related claims. **For additional information regarding the Settlement and procedures, please review the long-form Notice at www.strategicclaims.net/novavax/.** Your *pro rata* share of the Settlement proceeds will depend on the number of valid claims submitted, and when you purchased shares of Novavax. If all Settlement Class Members participate in the Settlement, the estimated average recovery will be \$1.24 per allegedly damaged share before deduction of Court-approved fees and expenses and approximately \$0.80 per share after. Your share of the Settlement proceeds will be determined by the plan of allocation set forth in the Notice, or such other plan that may be approved by the Court.

To qualify for payment, you must submit a valid Claim Form. Receipt of this Postcard does not mean you are eligible for a recovery. The Claim Form can be found at www.strategicclaims.net/novavax/, or you can request that one be mailed to you. You can also submit a claim via the website. **Claim Forms must be postmarked (if mailed) to: Novavax, Inc. Securities Settlement, c/o Strategic Claims Services, Inc., 600 N. Jackson St., Suite 205, P.O. Box 230, Media, PA 19063, or submitted online, by May 18, 2024. If you do not want to be legally bound by any releases, judgments or orders in the Action, you must exclude yourself from the Settlement Class by May 2, 2024.** If you exclude yourself, you may be able to sue Defendants about the claims being settled, but you cannot get money from the Settlement. **If you want to object to any aspect of the Settlement, you must file and serve an objection by May 2, 2024.** The Notice provides instructions on how to submit a Claim Form, exclude yourself, or object, and you must comply with all of the instructions in the Notice.

The Court will hold a hearing on **May 23, 2024 at 2:30 p.m.**, to consider whether to approve the Settlement and a request by Co-Lead Counsel for up to 33.4% of the Settlement Fund in attorneys’ fees, plus expenses of no more than \$1 million. You may attend the hearing and ask to speak, but do not have to. **For more information, call (866) 274-4004, email info@strategicclaims.net or visit the website to review the Notice.**